Evaluation of Clonidine Therapeutic Effect Added to Usual Treatment in Refractory Obsessive –Compulsive Disorder

Phase 3

Recruiting

• Conditions: obsessive compulsive disorder.; Obsessive-compulsive disorder

• Registration Number: IRCT20110918007582N2
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 14 January 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

The presence of obsessive-compulsive disorder criteria based on DSM-V-TR
Receive at least 12 weeks with a maximum dose of a serotonergic drug (SSRI or Clomipramine)
Moderate to severe symptoms based on the obsessive-compulsive- Yerobyll-Brown scale (YBOCS) with a score of more than 16
Obtain informed consent from the patient
No initial diagnosis of psychiatric disorders and mood disorder (bipolar or MDD)
Absence of drug use or dependence
There is no uncontrolled physical illness (such as diabetes, blood pressure, etc.)
There is no previous history of Clonidine use
Lack of pregnancy and lactation or planning for pregnancy during the study
There is no seizure disorder
No suicide attempt
Not taking beta-blocker
Failure to receive synchronous psychological intervention

Exclusion Criteria

Cancellation of participation in the study at each stage of the research
Pregnancy at each stage of the research

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
OCD Scale changes with YBOCS questionnaire. Timepoint: Before the intervention and at the end of 4-8-12 weeks. Method of measurement: Yale Brown Obsessive-Compulsive Scale (YBOCS).